KN026
Sponsors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Peking University Cancer Hospital & Institute, Peking University, Shanghai JMT-Bio Inc.
Conditions
Breast CancerEarly or Locally Advanced HER2-positive Breast CancerGastric CancerGastric/Gastroesophageal Junction CancerHER2-positive Biliary Tract CancerHER2-positive Colorectal CancerHER2-positive Gastric CancerHER2-positive Locally Advanced Resectable Gastric Cancer
Phase 1
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
CompletedNCT03619681
Start: 2018-09-17End: 2022-08-26Updated: 2024-03-12
KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer
NCT03847168
Start: 2019-06-18End: 2022-12-31Updated: 2021-11-17
Phase 2
Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
NCT04881929
Start: 2021-08-09End: 2023-02-15Target: 30Updated: 2022-06-22
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
Not yet recruitingNCT05985707
Start: 2023-08-15End: 2026-12-31Target: 80Updated: 2023-08-21
Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
RecruitingNCT06023758
Start: 2023-09-22End: 2026-12-31Target: 18Updated: 2024-05-10
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Not yet recruitingNCT06998771
Start: 2025-06-15End: 2029-12-31Target: 153Updated: 2025-05-31
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Not yet recruitingNCT07332533
Start: 2025-12-30End: 2032-12-31Target: 490Updated: 2026-01-12
Phase 3
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
RecruitingNCT06747338
Start: 2024-12-16End: 2027-12-16Target: 520Updated: 2025-04-24
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Not yet recruitingNCT07441460
Start: 2026-03-07End: 2035-08-07Target: 1800Updated: 2026-03-02